샘플 요청 목록

 카트 문의
시장보고서
상품코드
1568039

세계의 하이드록시클로로퀸 시장

Hydroxychloroquine
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 293 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

하이드록시클로로퀸 세계 시장은 2030년까지 13억 달러에 달할 것으로 전망

2023년 10억 달러로 추정되는 하이드록시클로로퀸 세계 시장은 2023-2030년 분석 기간 동안 연평균 3.1% 성장하여 2030년에는 13억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 말라리아 질환은 CAGR 4.5%를 기록하여 분석 기간 종료 시점에 6억 4,400만 달러에 도달할 것으로 예상됩니다. 류마티스 관절염 질환 부문은 분석 기간 동안 CAGR 2.1%의 성장률을 기록할 것으로 추정됩니다.

미국 시장 2억 8,420만 달러, 중국은 CAGR 6.3%로 성장 전망

미국의 하이드록시클로로퀸 시장은 2023년 2억 8,420만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023년부터 2030년까지 연평균 6.3%의 성장률을 보이며 2030년에는 2억 6,830만 달러의 시장 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 0.8%와 2.4%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 연평균 1.6%의 성장률을 보일 것으로 예상됩니다.

세계 하이드록시클로로퀸 시장 - 주요 동향 및 촉진요인 요약

하이드록시클로로퀸이란 무엇이며, 왜 전 세계적으로 주목받는가?

하이드록시클로로퀸은 원래 말라리아 치료를 위해 개발된 약물이지만, 이후 루푸스 및 류마티스 관절염과 같은 자가면역 질환 치료에 널리 사용되었습니다. 하이드록시클로로퀸은 면역 체계를 조절하고 염증을 억제하는 방식으로 작용하여 이러한 만성 질환에 대한 효과적인 치료 옵션이 될 수 있습니다. 화학적으로 하이드록시클로로퀸은 클로로퀸(또 다른 항말라리아제)의 유도체이지만 더 안전하고 부작용이 적은 것으로 알려져 있습니다. 최근 하이드록시클로로퀸은 COVID-19의 치료제로 사용될 수 있다는 논란이 일면서 전 세계적으로 그 어느 때보다 많은 관심을 받고 있습니다. 대유행 초기에는 바이러스 복제를 억제하고 면역 반응을 조절함으로써 바이러스의 심각성을 줄이는 데 도움이 될 수 있다는 예비 연구와 일화적인 증거가 몇 가지 있었습니다. 이 때문에 이 약에 대한 수요가 급증하고 전 세계적으로 관심이 높아져 일부 국가에서는 비축하거나 의사가 적응증 외로 처방하는 경우도 있었습니다. 그러나 이후 진행된 대규모 임상시험과 과학적 조사의 결과는 엇갈렸고, 그 효과에 대한 큰 논란과 혼란을 불러일으켰습니다. 세계보건기구(WHO)와 미국 식품의약국(FDA) 등 규제 기관은 처음에 긴급 사용 허가를 내렸지만, 결정적인 증거 부족과 잠재적 안전성 우려를 이유로 나중에 이를 취소했습니다. 이러한 지속적인 감시로 인해 하이드록시클로로퀸은 의학계뿐만 아니라 일반 사회에서도 계속 주목받고 있으며, 최근 가장 화제가 되고 있는 의약품 중 하나입니다.

하이드록시클로로퀸 사용자, 주요 의료 용도는?

하이드록시클로로퀸은 주로 루푸스 및 류마티스 관절염과 같은 자가면역 질환에 대한 질병 조절 항류마티스제(DMARD)로서 승인된 적응증으로 널리 사용되고 있습니다. 하이드록시클로로퀸은 만성 염증과 과도한 면역 반응을 경험하는 환자들에게 재발을 예방하고 증상을 조절하는 데 도움을 줍니다. 특히 루푸스 환자들에게 이 약은 피부 발진, 관절통, 피로를 조절하고 심각한 질병 발현에 따른 장기 손상을 예방하는 데 도움이 되는 등 매우 유용한 것으로 입증되었습니다. 류마티스 관절염에 대한 사용도 잘 알려져 있으며, 관절의 부종과 통증, 자가 면역 활동으로 인한 장기적인 손상을 완화하는 데 도움이 됩니다. 이러한 기존 용도 외에도 KEYWORD의 항말라리아제 역할은 말라리아가 유행하는 지역에서는 여전히 중요하지만, 현재는 주로 예방이나 새로운 항말라리아제에 대한 내성이 우려되지 않는 특정 상황에서 주로 사용되고 있습니다. 믹은 항바이러스 효과가 있다는 초기 보고에 힘입어 의료 전문가와 일반인 사이에서 적응증 외 사용이 급증했습니다. 이러한 적응증 외 사용은 의약품 부족으로 이어져 만성 질환으로 이 의약품에 의존하는 환자들의 접근성에 대한 우려를 불러일으켰습니다. 이러한 논란에도 불구하고, 쇼그렌 증후군과 유육종증을 포함한 다양한 다른 질환에서 KEYWORD의 면역 조절 및 항염증 작용은 계속 연구 대상으로 검토되고 있습니다. 이처럼 COVID-19 치료에서 하이드록시클로로퀸의 위치는 거의 부정되고 있지만, 하이드록시클로로퀸은 전 세계 수백만 명의 자가면역질환을 앓고 있는 사람들에게 중요한 약품임에는 변함이 없습니다.

하이드록시클로로퀸을 둘러싼 과제와 논란은 무엇인가?

하이드록시클로로퀸은 과학적 불확실성, 정치적 역학, 대중의 잘못된 정보로 인해 매우 복잡하고 복잡한 논쟁의 중심에 서 있습니다. 가장 큰 문제 중 하나는 승인된 적응증 외의 용도에 대한 안전성과 효능에 대한 데이터의 불일치이며, COVID-19 팬데믹 초기에는 소규모 관찰 연구와 시험관 실험에서 잠재적 효과가 제시되어 적응증 외 사용이 잇따랐습니다. 그러나 더 큰 규모의 무작위 대조 시험이 수행됨에 따라 많은 연구가 유의미한 임상적 이점을 보여주지 못했고, 일부는 부작용, 특히 부정맥이나 QT 연장과 같은 심혈관계 합병증을 보고하기도 했습니다. 이러한 일관성 없는 결과는 의료 제공자와 일반 대중 모두에게 혼란을 가져왔고, 과학적 연구와 규제 기관에 대한 신뢰를 떨어뜨렸습니다. 혼란을 더욱 가중시킨 것은 이 약이 정치적으로 이용되었다는 점입니다. 유명 인사들의 추천과 잘못된 정보 캠페인은 양극화된 논쟁을 불러일으켰고, 일반 대중의 인식은 더욱 혼란스러워졌습니다. 초기 과대 광고는 사재기, 비축, 경우에 따라서는 자가 투약의 확산으로 이어졌고, 그 결과 중독과 입원을 초래했습니다. 이러한 상황은 루푸스나 류마티스 관절염과 같은 만성 질환으로 하이드록시클로로퀸에 의존하는 환자에게는 품절로 인해 치료 계획이 중단되는 심각한 문제를 야기했습니다. 또한, 히드록시클로로퀸에 대한 규제 당국의 판단이 일관되지 않아 FDA와 유럽의약품청(EMA) 등의 기관이 긴급사용허가를 내주거나 취소하는 등 엇갈리는 모습을 보이고 있습니다. 이러한 규제 당국의 엇박자는 과학적 검증 과정과 공중보건 의사결정에서 정치의 역할에 대한 보다 광범위한 문제를 제기하고 있습니다. 이러한 논란에도 불구하고, 하이드록시클로로퀸의 승인된 사용법에 대한 안전성 프로파일은 여전히 잘 확립되어 있으며, 지난 몇 년간의 격변으로 인해 그 명성이 영향을 받은 것은 부인할 수 없는 사실입니다.

하이드록시클로로퀸에 대한 지속적인 관심의 요인은 무엇인가?

하이드록시클로로퀸에 대한 관심과 조사의 증가는 그 입증된 치료 효과, 진행 중인 과학적 연구, 비용 효율적인 치료 옵션의 탐색과 관련된 몇 가지 요인에 기인합니다. 주요 원동력 중 하나는 자가면역질환에 대한 안전하고 효과적인 치료제로 오랫동안 사용되어 왔으며, 루푸스 및 류마티스 관절염과 같은 질환의 치료에서 주요한 역할을 해왔다는 점입니다. 이러한 만성 질환 환자들에게 하이드록시클로로퀸은 다른 면역억제제에 비해 비교적 양호한 부작용 프로파일을 보이면서 질병 활동을 감소시키고 합병증을 예방하는 신뢰할 수 있는 약물임이 입증되었습니다. 이러한 효능이 입증됨에 따라 쇼그렌 증후군, 유육종증 등 염증이나 면역 조절 이상이 중요한 역할을 하는 다른 면역 매개 질환에 대한 적용 가능성을 모색하는 데에 대한 관심이 지속되고 있습니다. 또한, 저렴한 가격으로 널리 이용 가능하다는 점도 관심을 높이는 중요한 요인으로 작용하고 있습니다. 제네릭 의약품인 하이드록시클로로퀸은 새로운 면역조절제나 생물학적 제제에 비해 저렴하기 때문에 특히 의료 자원이 부족한 중저소득 국가에서 매력적인 대안이 될 수 있습니다. 또한, COVID-19에 대한 논란은 역설적으로 약리학적 특성에 대한 더 많은 연구에 박차를 가하고 있으며, 현재 일부 연구는 면역 조절 효과에 기여하는 작용 기전에 대한 정확한 이해에 초점을 맞추고 있습니다. 연구자들은 사이토카인 수치에 미치는 영향, 혈전성 합병증 예방에 대한 잠재적 효과, 면역 반응에 관여하는 다양한 신호 전달 경로에 미치는 영향 등을 조사하고 있습니다. 그 결과, 하이드록시클로로퀸은 알려진 용도뿐만 아니라 면역 조절 치료의 약리학적 전망에서 보다 광범위한 역할에 대한 과학적 탐구의 대상이 되고 있습니다.

조사 대상 기업 예시(총 56건)

  • Abcam PLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Daicel Chiral Technologies (India) Pvt. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Hetero Healthcare Ltd.
  • Ipca Laboratories Ltd.
  • Lifevision Healthcare
  • Lupin Ltd.
  • MilliporeSigma

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.10.17

Global Hydroxychloroquine Market to Reach US$1.3 Billion by 2030

The global market for Hydroxychloroquine estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Malaria Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$644.0 Million by the end of the analysis period. Growth in the Rheumatoid Arthritis Disease segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$284.2 Million While China is Forecast to Grow at 6.3% CAGR

The Hydroxychloroquine market in the U.S. is estimated at US$284.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$268.3 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Hydroxychloroquine Market - Key Trends and Drivers Summarized

What is Hydroxychloroquine, and Why Has It Garnered Global Attention?

Hydroxychloroquine is a medication that was originally developed to treat malaria but has since become widely used in the management of autoimmune disorders such as lupus and rheumatoid arthritis. It works by modulating the immune system and reducing inflammation, making it an effective therapeutic option for these chronic conditions. Chemically, hydroxychloroquine is a derivative of chloroquine, another antimalarial drug, but it is considered to have a better safety profile and fewer side effects. In recent years, hydroxychloroquine has gained unprecedented global attention due to its controversial and widely debated use as a potential treatment for COVID-19. Early in the pandemic, some preliminary studies and anecdotal evidence suggested that it might help in reducing the severity of the virus by inhibiting viral replication and modulating the immune response. This sparked a surge in demand and global interest in the drug, with some countries stockpiling it and doctors prescribing it off-label. However, subsequent large-scale clinical trials and scientific investigations yielded mixed results, leading to significant debate and confusion about its efficacy. Regulatory agencies like the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) initially issued emergency use authorizations but later revoked them, citing a lack of conclusive evidence and potential safety concerns. This ongoing scrutiny has kept hydroxychloroquine in the spotlight, not just in the medical community but also in public discourse, making it one of the most talked-about drugs of recent times.

Who is Using Hydroxychloroquine, and What Are Its Main Medical Applications?

Hydroxychloroquine continues to be widely used in its approved indications, primarily as a disease-modifying antirheumatic drug (DMARD) for autoimmune conditions like lupus and rheumatoid arthritis. Patients suffering from these disorders often experience chronic inflammation and an overactive immune response, and hydroxychloroquine helps by modulating these processes to prevent flare-ups and manage symptoms. For lupus patients, in particular, the drug has proven to be invaluable, helping to control skin rashes, joint pain, and fatigue, and preventing organ damage associated with severe disease manifestations. Its use in rheumatoid arthritis is also well-documented, where it helps reduce joint swelling, pain, and the long-term damage caused by autoimmune activity. Beyond these established applications, hydroxychloroquine’s role as an antimalarial agent remains relevant in regions where malaria is endemic, although it is now largely used for prevention and in specific cases where resistance to newer antimalarials is not a concern. The COVID-19 pandemic brought a surge of off-label use among both healthcare professionals and the general public, fueled by early reports suggesting potential antiviral properties. This off-label usage led to shortages and raised concerns about access for patients who depend on the drug for chronic conditions. Despite the controversies, hydroxychloroquine’s immunomodulatory and anti-inflammatory properties have kept it under consideration for research in various other diseases, including Sjögren's syndrome and sarcoidosis. Thus, while its place in COVID-19 treatment has been largely debunked, hydroxychloroquine remains a critical medication for millions suffering from autoimmune diseases worldwide.

What Challenges and Controversies Surround Hydroxychloroquine?

Hydroxychloroquine has been at the center of a highly charged and complex controversy, driven by a combination of scientific uncertainty, political dynamics, and public misinformation. One of the biggest challenges is the conflicting data surrounding its safety and efficacy for uses beyond its approved indications. Early in the COVID-19 pandemic, small observational studies and in vitro experiments suggested potential benefits, leading to a wave of off-label use. However, as larger randomized controlled trials were conducted, many failed to show any significant clinical benefits, and some even reported adverse effects, particularly cardiovascular complications like arrhythmias and QT prolongation. This inconsistency in results led to confusion among both healthcare providers and the public, eroding trust in scientific research and regulatory bodies. Adding to the confusion was the politicization of the drug, with high-profile endorsements and misinformation campaigns creating a polarized debate that further muddied public perception. The initial hype led to widespread hoarding, stockpiling, and in some cases, self-medication, which resulted in toxicity and hospitalizations. This situation posed significant challenges for patients who rely on hydroxychloroquine for chronic conditions like lupus and rheumatoid arthritis, as shortages disrupted their treatment regimens. Additionally, regulatory decisions regarding hydroxychloroquine have been inconsistent, with agencies such as the FDA and the European Medicines Agency (EMA) issuing and then retracting emergency use authorizations. This regulatory back-and-forth has raised broader questions about the process of scientific validation and the role of politics in public health decision-making. Despite these controversies, hydroxychloroquine’s safety profile for its approved uses remains well-established, though its reputation has been undeniably affected by the turbulence of the past few years.

What Factors Are Driving the Continued Interest in Hydroxychloroquine?

The growth in interest and research into hydroxychloroquine is driven by several factors related to its established therapeutic benefits, ongoing scientific inquiries, and the quest for cost-effective treatment options. One of the main drivers is its long-standing use as a safe and effective treatment for autoimmune disorders, making it a mainstay in the management of diseases like lupus and rheumatoid arthritis. For patients with these chronic conditions, hydroxychloroquine has proven to be a reliable medication that reduces disease activity and prevents complications, with a relatively favorable side effect profile compared to other immunosuppressive drugs. This established efficacy has sustained interest in exploring its potential applications in other immune-mediated diseases, such as Sjögren’s syndrome and sarcoidosis, where inflammation and immune dysregulation play a key role. Another key factor driving interest is its affordability and widespread availability. As a generic drug, hydroxychloroquine is inexpensive compared to newer immunomodulatory or biologic therapies, making it an attractive option, particularly in low- and middle-income countries where healthcare resources are limited. Moreover, the controversies surrounding its use in COVID-19 have paradoxically fueled more research into its pharmacological properties, with some studies now focusing on understanding the exact mechanisms of action that contribute to its immunomodulatory effects. Researchers are looking into its impact on cytokine levels, potential benefits in preventing thrombotic complications, and its influence on various signaling pathways involved in immune response. As a result, hydroxychloroquine remains a subject of scientific inquiry, not just for its known applications, but also for its broader role in the pharmacological landscape of immunomodulatory treatments.

Select Competitors (Total 56 Featured) -

  • Abcam PLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Daicel Chiral Technologies (India) Pvt. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Hetero Healthcare Ltd.
  • Ipca Laboratories Ltd.
  • Lifevision Healthcare
  • Lupin Ltd.
  • MilliporeSigma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Hydroxychloroquine - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Malaria in Endemic Regions Drives Growth in the Hydroxychloroquine Market
    • Increased Use of Hydroxychloroquine in the Treatment of Autoimmune Disorders Expands Market Potential
    • Growing Adoption for Rheumatoid Arthritis and Lupus Erythematosus Fuels Demand
    • Emerging Research on Hydroxychloroquine's Role in Managing Inflammatory Conditions Strengthens Market Scope
    • Rising Demand for Hydroxychloroquine in Developing Countries for Malaria Control Sustains Market Growth
    • Growing Emphasis on Chronic Disease Management Drives Long-Term Use of Hydroxychloroquine
    • Shifting Focus Towards Personalized Medicine in Autoimmune Disease Management Creates New Opportunities
    • Growing Use of Hydroxychloroquine in Combination Therapies Fuels Research and Development Initiatives
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hydroxychloroquine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hydroxychloroquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Malaria Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Malaria Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Malaria Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Rheumatoid Arthritis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Rheumatoid Arthritis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hydroxychloroquine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Hydroxychloroquine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Hydroxychloroquine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Hydroxychloroquine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제